2026 Pharma Services M&A Outlook

Industry report

Pharmaceutical and biotechnology companies continue to outsource development, manufacturing, and commercialization activities, supporting durable demand for specialized service providers across the drug lifecycle.

Download as PDF

Founders Group

Ali Naseer
Co-Founder & Partner
Ali@FoundersG.com (952) 797-4679
Matt Menzi
Co-Founder & Partner
Matt@FoundersG.com (301) 767-5616

EXECUTIVE SUMMARY

Pharma-services outsourcing remains durable, with capital concentrated in differentiated capabilities

Drug complexity, sponsor productivity pressure and supply-chain resilience support pharma services, while funding sensitivity and facility risk create wide dispersion.

Outsourcing is a structural industry requirement
Biopharma sponsors continue to rely on external specialists across development, manufacturing and commercialization.
Scaled assets attract strategic interest
Large buyers are paying for integrated clinical data, manufacturing capacity and specialty commercialization capability.
Clinical site networks remain active
Clinical-research platforms continue adding patient access, investigators and therapeutic-area expertise.
Changes in therapeutic modalities affect demand
Biologics, peptides, oligonucleotides and advanced therapies redirect demand toward specialized assets and talent.
Biotech funding conditions create volatility
Biotech budget pressure can affect early-development backlogs faster than commercial or late-stage services.
Quality systems influence transferability and valuation
Regulatory history, data integrity and technology transfer determine whether capacity is truly usable.

SECTOR AT A GLANCE

Six service categories span the drug- development and commercialization lifecycle

The relevant buyer set and valuation logic change with development stage, scientific specialization and capital intensity.

Exhibit 1

Investable lane	Business model	Primary buyer lens	Key risk
Discovery & preclinical	Research, models and safety studies	Scientific scarcity and sponsor relationships	Biotech funding
Clinical CRO services	Trial design, execution and data	Backlog quality and therapeutic expertise	Cancellations
Clinical trial site networks	Patient recruitment and site execution	Enrollment, investigators and density	Study concentration
CDMO & manufacturing	Development, scale-up and GMP production	Capacity, modality and regulatory record	Capex / utilization
Analytical & specialty labs	Testing, bioanalysis and release support	Methods, accreditation and turnaround	Equipment intensity
Regulatory & commercialization	Quality, market access and launch support	Talent, recurring clients and expertise	Project mix

MARKET UPDATE

Buyer interest is differentiating specialized capabilities from general capacity

Activity is stabilizing after a volatile period, with strategic and sponsor capital concentrating around integrated or specialized providers.

127: Estimated private-equity pharma-services deals in the latest half-year
Record: Recent scaled sponsor transaction value across the sector
$2.25bn: Newest disclosed strategic purchase of an integrated services platform

Exhibit 2

Theme	Market interpretation	Owner evidence that matters
Biotech funding	Early-stage research and small-biotech exposure remain more cyclical.	Segment backlog and cancellation rates by sponsor type.
Large-pharma productivity	Pipeline pressure supports continued outsourcing and capability acquisitions.	Show embedded relationships and repeat work by program stage.
Supply-chain resilience	Domestic and regional manufacturing capacity carries strategic importance.	Document capacity, transfer timeline and regulatory readiness.
Complex modalities	Peptides, injectables, biologics and advanced therapies require specialized assets.	Link technical capability to active programs and commercial potential.
Technology and AI	Automation can improve trial design, data review and laboratory throughput.	Quantify cycle-time, quality and labor benefits.

PRIVATE DEAL ACTIVITY

Private transaction activity is concentrated in clinical sites, specialty laboratories and scaled platforms

Sponsor-to-sponsor transactions and strategic acquisitions demonstrate long-term conviction despite uneven activity across early-development services.

Sites: One of the most consistently active consolidation lanes
CDMO: Capital is favoring differentiated modalities and usable capacity
Strategic: Large buyers are expanding integrated service offerings

Exhibit 3

Activity category	Buyer activity	Implications for owners
Clinical site networks	Platforms are adding investigators, patient populations and therapeutic-area depth.	Enrollment performance and site-level economics drive value.
Integrated clinical services	Strategics are combining data, diagnostics and trial execution.	Embedded workflow and sponsor relationships can create premiums.
CDMO	Large transactions focus on modality, scale and supply-chain control.	Utilization, transfer pipeline and inspection history remain central.
Analytical laboratories	Sponsors and strategics continue buying specialty assays and geographic capacity.	Methods, scientists and turnaround time can be scarce assets.
Commercialization	Market access, medical communications and launch support remain fragmented.	Recurring client relationships and therapeutic expertise matter.

BUYER LANDSCAPE

Strategic and financial buyers pursue different forms of control

Some buyers want a broad outsourced-services relationship; others want a single scarce capability that strengthens an existing platform.

Exhibit 4

Buyer type	Typical objective	What can create differentiated value	Common constraint
Global life-science strategics	Extend an integrated sponsor offering	Cross-sell, data integration and lower capital cost	Portfolio fit and regulatory integration
Scaled CRO / CDMO groups	Add capacity, modality or geography	Existing customers and operating infrastructure	Utilization and integration
Sponsor-backed platforms	Build density and capability through add-ons	Repeatable sourcing and shared commercial engine	Leverage and ownership horizon
New platform sponsors	Back a differentiated lower-middle-market anchor	Management, quality systems and whitespace	Scientific and customer concentration
Pharma / biotech strategics	Secure supply or internalize a critical capability	Direct program synergies and strategic scarcity	Make-versus-buy economics

VALUATION FRAMEWORK

Scientific scarcity and earnings durability drive pharma-services valuation

Two providers with similar EBITDA can trade very differently when one has commercial programs, differentiated modalities or embedded sponsor relationships.

6-9x: Common tuck-in band across established service models
9-15x: Common platform band for differentiated assets
Premium: Possible for scarce modalities, data or strategic workflow

Exhibit 5

Valuation lens	Why it matters	What strengthens the case
Program stage	Commercial and late-stage exposure generally improves visibility.	Map revenue and backlog by phase and probability.
Scientific differentiation	Scarce assays, modalities and expertise reduce substitution risk.	Connect capability to win rates and sponsor retention.
Quality and regulatory	Inspection history and data integrity protect the franchise.	Prepare complete audit, deviation and CAPA records.
Capacity utilization	Fixed-cost absorption materially affects CDMO and laboratory earnings.	Show capacity, constraints and transfer pipeline by site.
Customer quality	Large-pharma and diversified sponsor relationships can reduce funding risk.	Segment concentration, repeat work and cancellations.

VALUATION FRAMEWORK | FOUNDERS GROUP INDICATIVE RANGES

Specialized capabilities can support a material platform premium

Ranges are Founders Group guideposts for profitable lower-middle-market service providers—not quoted prices or a substitute for company-specific analysis.

Exhibit 6

Exhibit 7

Lens	What changes the outcome
Premium drivers	Commercial or late-stage programs; scarce modalities; strong quality record; recurring sponsor relationships; high retention; visible backlog; differentiated data; management depth.
Discount drivers	Biotech concentration; cancellation risk; idle capacity; warning letters; data-integrity issues; customer concentration; heavy capex; key-scientist dependence; weak systems.
Structure matters	Milestones, earnouts, rollover, working capital, deferred revenue, facility obligations and assumed regulatory liabilities can change proceeds at the same headline multiple.

SELECTED ANNOUNCED TRANSACTIONS | SCALED PLATFORMS

Large transactions are combining development, manufacturing and commercialization capabilities

Selected transactions illustrate strategic direction; they are not an exhaustive market sample.

Exhibit 8

Target / transaction	Buyer / ownership	Lane	Reported value	Strategic rationale
Catalent	Novo Holdings	CDMO	$16.5bn	Secures scaled development and manufacturing infrastructure
Clario	Thermo Fisher Scientific	Clinical data services	Up to $9.4bn	Integrates clinical-trial data and services
PCI Pharma Services	Sponsor consortium	CDMO / packaging	Not disclosed	Backs continued capacity and global expansion
Precision Medicine Group	McKesson	Clinical / commercialization	$2.25bn	Adds research and biopharma commercialization
CenExel Clinical Research	BayPine	Clinical site network	$1.5bn reported	Adds therapeutic depth and site infrastructure
Headlands Research	THL Partners	Clinical site network	$600m reported	Supports continued site-network consolidation
Syneos Health	Private sponsor consortium	CRO / commercialization	$7.1bn	Takes an integrated services platform private

SELECTED ANNOUNCED TRANSACTIONS | ADD-ONS AND CAPABILITIES

Add-on acquisitions are expanding patient access, methods, facilities and technical teams

Private transaction prices are usually undisclosed, but acquisition logic is visible in the capabilities buyers repeatedly pursue.

Exhibit 9

Target	Acquirer	Lane	Strategic rationale	Reported value
Clinical Trials Research	Headlands Research	Clinical sites	Adds investigators and patient access in a priority market	Not disclosed
Teddy Clinical Research Laboratory	Frontage Laboratories	Central laboratory	Strengthens global clinical-lab capability	Not disclosed
Sanofi Ridgefield site	Thermo Fisher Scientific	Drug-product manufacturing	Adds domestic sterile manufacturing capacity	Not disclosed
Pyramid Laboratories	Audax-backed platform	CDMO	Adds sterile fill-finish development and manufacturing	Not disclosed
Applied StemCell	QHP Capital	Cell and gene services	Creates a specialist CRO / CDMO platform	Not disclosed
Experimur	Frontage Laboratories	Preclinical testing	Adds toxicology and safety assessment capability	Not disclosed
Regional trial sites	Headlands and other site networks	Clinical sites	Adds patient pools, investigators and local density	Not disclosed

SUBSECTOR 1 OF 6

Discovery and preclinical services

Specialized science and high switching costs support value, while biotech funding and study timing create volatility.

6.0-9.0x EBITDA: Indicative tuck-in valuation
10.0-15.0x EBITDA: Indicative platform valuation
Studies + scientific expertise: Core economic model

Exhibit 10

Lens	Assessment
Buyer universe	Charles River; Thermo Fisher; Eurofins; Frontage; Altasciences; QHP and Audax-backed specialists; global research groups.
What buyers underwrite	Sponsor mix; repeat work; therapeutic expertise; backlog; cancellation; scientist retention; vivarium or lab utilization; regulatory history.
Current market developments	Buyers are favoring differentiated models, complex assays and integrated early-development workflows over general capacity.
Principal risks	Small-biotech exposure; study delays; animal-model regulation; key-scientist dependence; facility utilization; customer concentration.

Selected market signal

Private platforms continue adding specialist preclinical and cell-and-gene capabilities where scientific know-how is difficult to recreate.

SUBSECTOR 2 OF 6

Clinical CRO services

Embedded sponsor relationships and therapeutic expertise support value, but backlog conversion and cancellation risk require careful diligence.

6.0-9.0x EBITDA: Indicative tuck-in valuation
9.0-13.0x EBITDA: Indicative platform valuation
Backlog + project execution: Core economic model

Exhibit 11

Lens	Assessment
Buyer universe	IQVIA; ICON; Parexel; Fortrea; Medpace; Thermo Fisher / PPD; Syneos; specialist CRO platforms.
What buyers underwrite	Backlog; net awards; book-to-bill; cancellation; sponsor mix; therapeutic area; staffing; utilization; project margin; investigator and site access.
Current market developments	Integrated buyers are combining trial execution, data and diagnostics while specialist CROs compete through scientific and therapeutic focus.
Principal risks	Backlog slippage; fixed-price contracts; biotech concentration; employee utilization; project overruns; technology displacement.

Selected market signal

Large strategic transactions show value in clinical data and workflow that sit close to sponsor decision-making.

SUBSECTOR 3 OF 6

Clinical trial site networks

Patient recruitment, investigator quality and reliable enrollment are driving one of the most active pharma-services consolidation lanes.

6.0-9.0x EBITDA: Indicative tuck-in valuation
9.0-13.0x EBITDA: Indicative platform valuation
Enrollment + site density: Core economic model

Exhibit 12

Lens	Assessment
Buyer universe	Headlands Research; CenExel; Flourish Research; Alcanza; Velocity Clinical Research; Elligo; regional site networks.
What buyers underwrite	Enrollment against plan; investigator retention; therapeutic mix; site contribution; sponsor relationships; startup time; patient database; quality.
Current market developments	Sponsor-backed networks continue to buy independent sites and invest in centralized recruiting, technology and business development.
Principal risks	Study concentration; principal-investigator dependence; delayed starts; screen failures; patient-acquisition cost; inconsistent site operations.

Selected market signal

Recent platform transfers and continuing site add-ons demonstrate conviction in scaled patient-access networks.

SUBSECTOR 4 OF 6

CDMO and manufacturing services

Usable capacity, modality specialization and a clean regulatory record can command premiums; idle assets and transfer risk can erase them.

6.0-10.0x EBITDA: Indicative tuck-in valuation
10.0-15.0x EBITDA: Indicative platform valuation
Capacity + program lifecycle: Core economic model

Exhibit 13

Lens	Assessment
Buyer universe	Thermo Fisher / Patheon; Catalent; Lonza; PCI Pharma; Cambrex; Curia; CordenPharma; Siegfried; Recipharm; strategic sponsors.
What buyers underwrite	Capacity by line; utilization; development pipeline; commercial programs; tech transfer; inspection history; customer concentration; maintenance capex.
Current market developments	Capital is moving toward sterile fill-finish, biologics, peptides and other complex modalities, alongside renewed interest in regional supply resilience.
Principal risks	Inspection findings; validation delays; underutilization; major-customer loss; fixed-price development work; capex overruns; environmental risk.

Selected market signal

Scaled acquisitions and facility transfers show that buyers will pay for capacity that can be qualified and productive without a long build cycle.

SUBSECTOR 5 OF 6

Analytical and specialty laboratory services

Methods, accreditation and technical turnaround create recurring demand across development, release and post-market testing.

6.0-9.0x EBITDA: Indicative tuck-in valuation
10.0-14.0x EBITDA: Indicative platform valuation
Methods + lab throughput: Core economic model

Exhibit 14

Lens	Assessment
Buyer universe	Eurofins; SGS; Thermo Fisher; Frontage; Pace Analytical; specialist bioanalytical and central-lab platforms.
What buyers underwrite	Method ownership; validation; sample volume; turnaround; repeat testing; scientist retention; equipment utilization; chain of custody; quality events.
Current market developments	Buyers continue to add central-lab, bioanalytical, release-testing and specialty-assay capabilities that deepen sponsor relationships.
Principal risks	Equipment capex; data integrity; lab underutilization; method transfer; scientist concentration; sample logistics; accreditation scope.

Selected market signal

Recent laboratory add-ons emphasize global coverage and specialty capability rather than simple square footage.

SUBSECTOR 6 OF 6

Regulatory, quality and commercialization services

Specialized talent and recurring client relationships create attractive asset-light models, with AI changing delivery economics rather than eliminating demand.

5.5-8.5x EBITDA: Indicative tuck-in valuation
9.0-13.0x EBITDA: Indicative platform valuation
Talent + recurring programs: Core economic model

Exhibit 15

Lens	Assessment
Buyer universe	Precision Medicine Group; Red Nucleus; Indegene; Envision Pharma; market-access and regulatory platforms; global consulting strategics.
What buyers underwrite	Client retention; recurring versus project work; therapeutic expertise; utilization; realization; senior-talent concentration; offshore mix; data security.
Current market developments	Integrated platforms are combining regulatory, medical communications, market access and commercialization to serve sponsors across the product lifecycle.
Principal risks	Project lumpiness; key-person risk; procurement pressure; AI-enabled insourcing; utilization; client concentration; data privacy.

Selected market signal

A scaled strategic acquisition of an integrated clinical and commercialization platform shows the value of owning customer workflow beyond laboratory or manufacturing capacity.

CONSOLIDATOR LANDSCAPE

Relevant buyers include global strategic acquirers and focused private platforms

Representative consolidators and ownership reflect the 2H26 market; the list is not exhaustive.

Exhibit 16

Lane	Representative sponsor-backed / private	Representative strategic / public	Typical acquisition logic
Discovery / preclinical	Altasciences; QHP and Audax-backed specialists	Charles River; Thermo Fisher; Eurofins; Frontage	Models, assays and scientific expertise
Clinical CRO	Syneos; Parexel and private specialist CROs	IQVIA; ICON; Fortrea; Medpace; Thermo Fisher / PPD	Backlog, therapeutic depth and data
Clinical sites	Headlands; CenExel; Flourish; Alcanza; Velocity	Large CRO partnerships and healthcare strategics	Patients, investigators and enrollment
CDMO	PCI Pharma; Cambrex; Curia; Recipharm; private platforms	Thermo Fisher; Catalent; Lonza; Siegfried	Modality, capacity and supply resilience
Laboratories	Specialist bioanalytical and central-lab platforms	Eurofins; SGS; Thermo Fisher; Frontage	Methods, coverage and turnaround
Regulatory / commercial	Red Nucleus; private market-access platforms	McKesson / Precision; Indegene; global consultancies	Talent, workflow and client access

OWNER PREPARATION AND MARKET OUTLOOK

Present scientific capability as a transferable commercial asset

Buyer diligence must establish that demand, quality systems and technical execution will remain durable after a change in ownership.

Exhibit 17

	Preparation priority	Required evidence
1	Segment revenue by program stage	Show discovery, development, late-stage and commercial exposure, with cancellations and repeat work.
2	Prove backlog quality	Reconcile awards, contracted backlog, expected timing, pass-through costs and historical conversion.
3	Prepare quality diligence	Organize inspection, deviation, CAPA, data-integrity, validation and customer-audit histories.
4	Quantify capacity and utilization	Map bottlenecks, available capacity, transfer pipeline and required maintenance or growth capex.
5	Reduce technical key-person risk	Document methods, project governance, succession and the depth of scientific and quality leadership.
6	Position strategic scarcity	Explain why the buyer would struggle to build the capability, access the patients or replicate the customer workflow.

Founders Group outlook

Clinical site networks should remain active as platforms pursue enrollment performance and therapeutic depth. CDMO valuation will stay dispersed between differentiated, utilized capacity and general or underused assets. Integrated clinical-data and commercialization capabilities should continue attracting strategic interest. Early-development businesses will remain more sensitive to biotech funding and sponsor concentration.

ABOUT THIS REPORT

Use this report as market context, not as a valuation opinion

A 2H26 view of private deal activity, consolidators, valuation context and owner priorities across Pharma Services.

Methodology

Market observations reflect current transaction patterns, disclosed consideration and operating developments across outsourced pharma services. Disclosed multiples are shown only when transaction value and a matching earnings measure were public. Founders Group indicative ranges triangulate private-market behavior, disclosed precedents and subsector judgment; they should not be read as a fairness opinion or valuation conclusion.

1: Market observations Current transaction patterns and operating themes.
2: Disclosed transactions Values are shown only when transaction consideration was public.
3: Indicative ranges Founders Group judgment based on size, quality and buyer behavior.

Exhibit 18

Term	Meaning in this report
Tuck-in	A smaller acquisition integrated into an existing platform. Strategic fit, geography, capability and customer density may influence value.
Platform	A business capable of standing alone as a buyer's sector anchor, with management, systems and a repeatable growth model.
Enterprise value / EBITDA	A valuation ratio comparing enterprise value with adjusted earnings before interest, taxes, depreciation and amortization.
Indicative range	A market guidepost rather than a quoted price. Actual outcomes depend on company-specific facts, structure and process.

Disclaimer

This material is for general informational purposes only and does not constitute investment, legal, tax, accounting or valuation advice, an offer to sell, or a solicitation to buy any security. Information is believed reliable but has not been independently verified and may be incomplete. Actual transaction outcomes depend on company-specific facts, market conditions, structure and process. Past transactions and market observations are not indicative of future results.

Founders Group

Ali Naseer
Co-Founder & Partner
Ali@FoundersG.com (952) 797-4679
Matt Menzi
Co-Founder & Partner
Matt@FoundersG.com (301) 767-5616

San Francisco · Denver · Minneapolis · New Yorkwww.foundersg.com

Download the PDF version

Pharma Services